Post on 07-Apr-2018
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
1/32
Collaborating with AcademiaFrom sparring with shadows to waltzing with Wanda
Pharma R&D World Asia Congress
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
2/32
Summary Academia has always been a major source of pharmaceutical innovations With new changes in the research environment, this dependence is set to
increase Support for academic R&D in OECD countries is decelerating India/China are ramping up support for academic R&D; this is coupled to
rapid expansion in GDP The academic sector in emerging nations is poised to play an important
role as a source of innovation The translational gap is still to be effectively bridged: Examples ofinnovative Indian models being created within the academic/GOI sector to bridgethis gap
How can we use the clean stage for a waltz rather than a sparring session:
Some examples from Merck What more could Pharma do?
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
3/32
Industry R&D owes its origins to academia
Alfred Newton Richards, 1876 1966
Prof of Pharmacology Univ of PennsylvaniaAnd Consultant andBoard Member, Merck and Co., Inc.
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
4/32
Dorsey, E. R. et al. JAMA 2010;303:137-143
Support for academic R&D in the US is deceleratingFunding by source: 2003-2007
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
5/32
NIH budget appropriation (1960-2010)
0
5,000,000
10,000,000
15,000,000
20,000,000
25,000,000
30,000,000
35,000,000
1950 1960 1970 1980 1990 2000 2010 2020
Support for academic R&D in the US is decelerating
Source: NIH
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
6/32
Growth of articles published in peer-reviewed journals
%C
HANGE
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
7/32
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
8/32
Why drug discovery in academia
Increasing specialization of knowledge and research skills in life science
Specialists have a natural home in academia
Synergy/complementarity between applied and basic aspects
Cost of exploratory science
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
9/32
Who will mind the translational gap?
Academia Industry
Educationalgovernance
Regulatorygovernancequantity
qu
ality
DATA
GAP
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
10/32
Innovative Organization Structures
Examples from India
OSDD Open Source Drug Discovery
CCAMP Center for Advanced Molecular Platforms
THSTI Translational Health Sciences and TechnologyInstitute
ILS Institute for Life Sciences
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
11/32
Sponsored by CSIR/GOI (USD 38 million)
Collaborative platform for Indian scientists and theirglobal counterparts for solving problems related toneglected tropical diseases
Aggregation of biological and genetic information tohasten drug discovery
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
12/32
MECHANICS
The sub-division of activities into work packages enables adivide and conquer approach
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
13/32
PEER REVIEW BASEDMICROATTRIBUTION USINGWEIGHTED CREDITS
TIERED MEMBERSHIP
MONETARY + NON-
MONETARY REWARDS
SHARING REWARDS
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
14/32
Translational Health Sciencesand Technology Institute
Faridabad, India
Translational research focus
Collaboration with Harvard-MIT
Centers:Vaccine and infectious diseaseClinical Development ServicesPediatric biologyBiodesign
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
15/32
A Component of the
Bangalore Bio-Cluster
Invention Innovation
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
16/32
Technology Platforms
Confocal
& Fluorescence
Microscopy
(Services and Training)
Flow Cytometry
(Services and Training)
Mass Spectrometry andProteomics
(Services)
Transgenic Fly Facility
(Services)
High Throughput
Screening
(Services)
High-end Genomics (Next Generation Sequencing)
Intellectual Property Management Office (IPMO) and
Technology Transfer Office
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
17/32
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
18/32
Govt. of Andhra Pradesh
PUBLIC
University of Hyderabad
PRIVATE
Public-Private Partnership
http://piramalhealthcare.com/index.aspx8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
19/32
To find solutions to improve human health
through the application of cutting edgeresearch by integrating various disciplines ofSciences (Life, Information, Chemical &Physical)
Translational Research
Bridge the gap between industry andacademic centres
Aligned to the needs of Pharma / Biotechindustry
MISSION and OBJECTIVES
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
20/32
Merck is Dedicated to Academic Partnerships
Merck scientists welcome the opportunity to collaborate with ouracademic colleagues to advance the state of the art in biomedical
research.
Together with our academic partners, we areexploring novel research models to advance
cutting-edge science into new medicines thataddress important unmet medical needs.
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
21/32
For Academic Collaborations,
Mercks Approach is Driven by Strategy
Defining goals, delivering against a work plan, and respecting intellectualproperty are the keys to a successful collaboration.
Well defined goals are critical
Objective to produce new knowledge advancing research/productdevelopment
May be strategic (breakthrough science) or tactical (an acceptedapproach, but elegantly executed)
Funding is based on the work plan, not for general lab support
Milestones / Renewal based on delivering on objectives
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
22/32
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
23/32
23
Moffitt Collaboration:
Personalized Medicine to Treat Cancer (2006) Collaboration to link molecular technology and clinical
data to enhance the ability to diagnose and treat patients,
and to discover and develop new targeted therapies(Dec. 2006)
Identify the right drug for the right patient - individualize
treatment for patients with various types of cancer
Partnership between patients, community
providers, industry and government to personalizeand improve cancer care
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
24/32
Merck/Moffitt Collaboration: Direct patient selectionfrom database matching molecular signatures to
clinical trialsProfiles stored at hospital
Diseaserecurrence
and trialeligibility
Validation of molecular hypotheses
Patient selection on available profiling data
Trial sig B
Clinical trial Portfolio
Trial sig A
Trial sig C
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
25/32
Dana-Farber and Merck CreateTeam Approach to Cancer Drug Treatment (2008)
To improve the success rate of investigational cancer drugs enteringclinical trials, the Belfer Institute for Applied Cancer Science (BIACS)
of the Dana-Farber Cancer Institute and Merck and Co., Inc., haveestablished a collaboration to identify promising drug targets, anddevelop therapeutic candidates to reach those targets.
The BIACS will investigate drug targets using integrative and cross-species genomic analysis and stringent multi-level functional andclinicopathological validation testing.
The BIACS will work together with Merck to shepherd the drug assay
development of lead compound discovery and then work together totest these drugs in BIACS's highly sophisticated model systems thatclosely replicate human disease.
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
26/32
Driving Innovation through Partnering
Mercks agreement with Harvard University on new treatmentsfor osteoporosis
Example of a new breed of industry-academia alliances with closeconnections between the teams
Jointly design project proposals, jointly do research, patent and publishresults together
Translational Medicine: Accelerate the move from
basic biology drug targets medicines
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
27/32
Harvard/Merck Collaboration
Merck is using their enormous resources to help us assemblehuge expression arrays and integrate the signaling pathways in
samples we give them.
The two lead Harvard scientists on the project interact with Merckalmost daily. The team gets together once a month, and all
participants have access to a virtual meeting room where they canpost data. We feel like it really is a research collaboration.
Dr. Laurie H. Glimcher
Professor, Harvard Medical SchoolProfessor of Immunology, Harvard School of Public Health
Chemical & Engineering News (Nov. 17, 2008)
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
28/32
Abacus is a unique forum for exchange of ideas betweenMRL and selected Imperial College faculty
Goals are to build an open exchange of ideas and people on afoundation of trust and collaboration resulting in inspired innovativethinking that ultimately translates into the design of novelhealthcare solutions
Develop novel approaches that improve patient care/outcomes andare valued in the market place
Active exchange of individuals who benefit from the exposure to the
respective environments.
Abacus Project -- Imperial College London
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
29/32
MERCK
Participation in a new model ofacademic interactions
External linkages
Access to and collaborationwith experts outside of Merckcore competencies
Access to unique knowledgenot targeted to a product:seed of blue skies innovation
New ideas
Sabbatical opportunitiesPublications
IMPERIAL COLLEGE
Catalyze and facilitate interactions
between diverse departments in thearea of systems biology
Potential for financial reward throughcommercial viability
Publications
Educational exchange opportunities -selected faculty and students
Leverage additional resources frome.g government/charity
Abacus Project -- Imperial College London
ABACUS
Develop novel approaches that improve patient care/outcomes and arevalued in the market place
Active exchange of individuals who benefit from the exposure to therespective environments.
29
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
30/32
Medarex and Mass Biologic Labs:Agreement with Merck for Investigational Antibody
for C. difficileInfection (April 09) Exclusive worldwide licensing agreement for CDA-1 and CDB-1, an
investigational fully human monoclonal antibody combination developed totarget and neutralize Clostridium difficiletoxins A and B, for the treatment of
C. difficileinfection (CDI).
CDA-1 and CDB-1 were co-developed by Medarex and MBL. Merck gainsworldwide rights to develop and commercialize CDA-1 and CDB-1.
Top-line results from a Phase II multicenter, randomized, double-blind,placebo-controlled trial evaluating CDA-1/CDB-1 provided evidence of astatistically significant reduction in the rate of recurrence of CDI comparedwith placebo.
This agreement underscores Mercks ongoing commitment to infectious
disease research and the licensing of promising candidates with the potentialto address serious unmet medical needs.
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
31/32
UTSA, Health Science Center: Collaboration with
Merck to Develop Chlamydia Vaccine (April 09) The University of Texas at San Antonio (UTSA) and the University of Health
Science Center at San Antonio (Health Science Center) will work with Merckon a vaccine for chlamydia, targeting the common sexually transmittedbacterium Chlamydia trachomatis.
Merck will fund research at UTSA and the Health Science Center andcollaborate closely with their team of researchers who have demonstratedthat, in animal models of genital chlamydial infection, a vaccine composed of
a select group of recombinant C. trachomatisantigens can successfullyaccelerate bacterial clearance, and importantly, preserve female reproductivefunction.
The partnership is an exciting development in the fight against infectious
disease and aligns with Mercks commitment to R&D in areas of unmetmedical need.
8/6/2019 Collaboration With Academia - From Sparring With Shadows Final
32/32
What Pharma can do (better) in Emerging
Markets academic sector engagements Relationship building is still important
Customize relationships to unique needs while takingadvantage of unique situations
Help catalyze the development of novel organizationstructures (do not wait for things to happen!)
Be sensitive/respectful towards the primary mission ofemerging market institutions